Cancer HorizonsAll NewsBlogsCaregivingDiet and ExerciseFinancialPsychosocialRecipesSexual HealthSide EffectSponsoredSurvivorship
All VideosCURE ConnectionsCURE Expert Connections®CURE Speaking OutCURE TVEducated Patient Sound BitesOn Demand: Webinars
Conference Coverage Conference Listing
CURE AdventuresCURE AwardsEducated Patient In Person EducationEducated Patient Virtual Education
Advocacy GroupsArt GalleryClinical Trial CornerHeal®PartnersPodcastsPublicationsShare Your Story
Subscribe
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
Immunotherapy
LeukemiaLeukemiaLeukemia
Lung CancerLung Cancer
LymphomaLymphomaLymphomaLymphomaLymphoma
Myeloma
Rare CancersRare CancersRare CancersRare Cancers
Sarcoma
Skin CancerSkin Cancer
Thyroid Cancer
Spotlight -
  • Blogs
  • Breast Cancer Webinar Series
  • Cancer Horizons
  • Clinical Trial Corner
  • Heal®
  • Publications
  • Videos
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
Immunotherapy
LeukemiaLeukemiaLeukemia
Lung CancerLung Cancer
LymphomaLymphomaLymphomaLymphomaLymphoma
Myeloma
Rare CancersRare CancersRare CancersRare Cancers
Sarcoma
Skin CancerSkin Cancer
Thyroid Cancer
    • Subscribe
Advertisement

Article

October 3, 2022

Understanding The Basics of VHL-Related Kidney Cancer

Author(s):

Brielle Benyon

An expert explains the basics of von Hippel-Lindau—related kidney cancer, and how a new drug for the disease is shaping the way patients are treated.

Patients with von Hippel-Lindau (VHL) disease are prone to developing tumors — both cancerous and non-cancerous — throughout their life.

Traditionally, patients with VHL-related kidney cancer were treated with surgery or ablation (a process that involves sending heat or cold to destroy the tumor). However, last summer the Food and Drug Administration (FDA) approved Welireg (belzutifan), a targeted therapy for patients with VHL-associated kidney cancer.

VHL disease-associated kidney cancer can occur early, (such as when patients are in their) 20s to 30s and is often multifocal and in both kidneys, according to an expert at The University of Texas MD Anderson Cancer Center in Houston.

VHL disease-associated kidney cancer can occur early, (such as when patients are in their) 20s to 30s and is often multifocal and in both kidneys, according to an expert at The University of Texas MD Anderson Cancer Center in Houston.

In an interview with CURE®, Dr. Eric Jonasch, a professor in the Department of Genitourinary Medical Oncology at The University of Texas MD Anderson Cancer Center in Houston, discussed the basics of VHL-related kidney cancer, and how Welireg is changing the treatment trajectory for the disease.

READ MORE: VHL-Related Kidney Cancer Survivor Reflects on Decades of Change for the Rare Condition

CURE®: Can you explain what VHL is, and the cancers associated with it?

Jonasch: VHL disease is an inherited autosomal dominant germline genetic disorder which affects around 10,000 people in the United States. People with VHL disease have benign and cancerous tumors in their eyes, brain, spine, pancreas, adrenal gland, kidneys, inner ear and reproductive organs.

VHL disease associated kidney cancer can occur early, (such as when patients are in their) 20s to 30s and is often multifocal and in both kidneys.

What is the current treatment standard(s) of care for VHL-associated kidney cancer, and who should be tested for VHL?

Prior to the approval of Welireg, individuals would undergo surgery for tumors that approached 3 centimeters in size or undergo ablation. Since August 2021, we have the option of treating patients with an oral drug called Welireg, which has been shown to result in significant shrinkage of kidney tumors in more than half of the patients treated with this drug.

If a person diagnosed with clear cell kidney cancer is younger than 46, has multiple kidney tumors, has hemangioblastomas (a type of non-cancerous tumor) in the brain, pancreatic cysts or pancreatic neuroendocrine tumors, or has a strong family history of VHL disease, germline testing for VHL disease is appropriate.

What is the grand takeaway that patients need to know about VHL-associated kidney cancer?

In 2022, although careful follow-up with regular scans and a strong treatment team experienced in VHL disease is still really important, with Welireg, we finally have a treatment that will likely decrease the number of surgeries and interventions patients need to undergo in their lifetimes.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Although late-stage kidney cancer generated poor survival rates for over two decades, significant progress is being made in the treatment of the disease.
CURE spoke with Dr. William C. Huang about what kind of team may be required to treat a patient with metastatic kidney cancer.
Dr. Alan Tan is a genitourinary oncology (GU) and melanoma specialist at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee; an associate professor of medicine in the Division of Hematology and Oncology at Vanderbilt University Medical Center; and GU Executive Officer with the Alliance for Clinical Trials in Oncology.
Dr. David A. Braun, an Assistant Professor of Medicine, Medical Oncology, and a Louis Goodman and Alfred Gilman Yale Scholar, at the Yale School of Medicine, as well as a member of the Center of Molecular and Cellular Oncology at Yale Cancer Center, in New Haven, Connecticut
Image of Dr. Braun.
Image of a man with short black hair.
Image of a man with short black hair.
Dr. Giles in an interview with CURE
Related Content
Advertisement
March is Kidney Cancer Awareness Month, and voices like Sid Sadler are raising awareness: © Axel Kock - stock.adobe.com
March 27th 2025

Kidney Cancer Awareness Month Highlights Advocacy and Early Detection

Ryan Scott
March is Kidney Cancer Awareness Month, highlighting the disease, early detection and and patient advocacy, with voices like Sid Sadler raising awareness.
Image of kidneys.
January 28th 2025

Identifying Drivers of Exceptional Response to Immunotherapy in Metastatic RCC

Ryan Scott
In patients with RCC, exceptional response to immunotherapy may be related to clonal neoantigen-driven cytotoxic T-cell responses, among other factors.
Image of a doctor sitting next to a patient.
September 26th 2024

Palliative Care in Kidney Cancer More Than Just Relieving Symptoms

Ashley Chan
Patients with kidney cancer who want more support during treatment can consider palliative care, whether it’s for symptoms or discussing goals and values.
Illustration of a person's kidneys.
June 24th 2024

Expectations for Postsurgical Treatments in Kidney Cancer

Ashley Chan
For patients with kidney cancer undergoing postsurgical treatments, it’s key to understand how immunotherapy works and what side effects to look for.
Image of a patient receiving radiation therapy.
March 29th 2024

What Patients With Kidney Cancer Need to Know About Radiation Therapy

Alex Biese
An expert explains what patients need to keep in mind and what conversations they should be having with their care teams.
cancer detecting CAR-T cell therapy
November 13th 2023

CAR-T Cell Therapy Is ‘Exciting’ in Advanced Kidney Cancer

Caroline Seymour
While CAR-T cell therapy is showing promise in treating patients with advanced renal cell carcinoma, there is still more research that needs to be done in this arena.
Related Content
Advertisement
March is Kidney Cancer Awareness Month, and voices like Sid Sadler are raising awareness: © Axel Kock - stock.adobe.com
March 27th 2025

Kidney Cancer Awareness Month Highlights Advocacy and Early Detection

Ryan Scott
March is Kidney Cancer Awareness Month, highlighting the disease, early detection and and patient advocacy, with voices like Sid Sadler raising awareness.
Image of kidneys.
January 28th 2025

Identifying Drivers of Exceptional Response to Immunotherapy in Metastatic RCC

Ryan Scott
In patients with RCC, exceptional response to immunotherapy may be related to clonal neoantigen-driven cytotoxic T-cell responses, among other factors.
Image of a doctor sitting next to a patient.
September 26th 2024

Palliative Care in Kidney Cancer More Than Just Relieving Symptoms

Ashley Chan
Patients with kidney cancer who want more support during treatment can consider palliative care, whether it’s for symptoms or discussing goals and values.
Illustration of a person's kidneys.
June 24th 2024

Expectations for Postsurgical Treatments in Kidney Cancer

Ashley Chan
For patients with kidney cancer undergoing postsurgical treatments, it’s key to understand how immunotherapy works and what side effects to look for.
Image of a patient receiving radiation therapy.
March 29th 2024

What Patients With Kidney Cancer Need to Know About Radiation Therapy

Alex Biese
An expert explains what patients need to keep in mind and what conversations they should be having with their care teams.
cancer detecting CAR-T cell therapy
November 13th 2023

CAR-T Cell Therapy Is ‘Exciting’ in Advanced Kidney Cancer

Caroline Seymour
While CAR-T cell therapy is showing promise in treating patients with advanced renal cell carcinoma, there is still more research that needs to be done in this arena.
About Us
Advertise / Support
Editorial Board
Contact Us
CancerNetwork.com
TargetedOnc.com
OncLive.com
OncNursingNews.com
Terms & Conditions
Privacy
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.